Analytical Data
-
Gene name
TMEM25
- Application
-
Alternative Names
0610039J01Rik; FLJ14399; Tmem25; TMM25_HUMAN; Transmembrane protein 25
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86YD3
-
Expression Region
27-322aa
-
Molecular Weight
48.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TMIGD1, or Transmembrane Immunoglobulin and mucin domain-containing protein 1, is an emerging protein of interest in immunology and cancer research due to its proposed roles in cell signaling and regulation of immune responses. TMIGD1 is primarily expressed in various immune cells, including T cells and dendritic cells, suggesting its involvement in modulating immune functions. Recent studies have indicated that TMIGD1 may play a crucial role in promoting T cell activation and proliferation, as well as influencing the balance between different immune responses, such as Th1/Th2 polarization. Given its potential as a therapeutic target, understanding the structural and functional characteristics of recombinant TMIGD1 is critical. Researchers have been focusing on the production and characterization of recombinant TMIGD1 to elucidate its mechanisms of action in immune modulation and its implications in diseases like cancer and autoimmune disorders. The development of recombinant TMIGD1 allows for detailed biochemical analysis and functional assays, paving the way for innovative therapeutic strategies aimed at enhancing immune responses or inhibiting tumor growth. Thus, the investigation of TMIGD1 not only contributes to our understanding of immune regulation but also holds promise for the development of novel immunotherapeutic approaches.
